Key Words: omega 3 PUFA Ⅲ PPAR Ⅲ retinopathy Ⅲ neovascularization Ⅲ oxygen-induced retinopathy P roliferative retinopathy is a major cause of blindness that occurs in 2 stages. Loss of functional vasculature in the early phase leads to retinal hypoxia that in turn drives a compensatory but destructive growth of pathological neovessels in the later phase. We previously found that dietary 3-PUFAs given before the onset of neovascularization in the oxygen-induced retinopathy (OIR) mouse model stimulate the regrowth of normal retinal vasculature, 1 thus limiting the hypoxic stimulus for subsequent proliferative retinopathy. It is, however, not known if 3-PUFAs also have direct effects on retinal neovascularization (NV) formation and what mechanisms might be involved in mediating this effect.
P roliferative retinopathy is a major cause of blindness that occurs in 2 stages. Loss of functional vasculature in the early phase leads to retinal hypoxia that in turn drives a compensatory but destructive growth of pathological neovessels in the later phase. We previously found that dietary 3-PUFAs given before the onset of neovascularization in the oxygen-induced retinopathy (OIR) mouse model stimulate the regrowth of normal retinal vasculature, 1 thus limiting the hypoxic stimulus for subsequent proliferative retinopathy. It is, however, not known if 3-PUFAs also have direct effects on retinal neovascularization (NV) formation and what mechanisms might be involved in mediating this effect.
In this study, we expose mice to 3-PUFAs exclusively during the peak proliferative stage (phase II) of retinopathy. With this approach 3-PUFAs selectively target retinal NV formation, without affecting vasoobliteration or regrowth of normal vessels. Our results demonstrate that 3-PUFAs given after the onset of active retinopathy exert a beneficial effect on the inflammatory and angiogenic activation state of the retina that, mediated via the endogenous 3-PUFA receptor peroxisome proliferator-activated receptor (PPAR)␥, leads to attenuated retinal NV. concentration 6 that effectively blocks PPAR␥ in vivo 7 was injected IP daily into mouse pups from P14 to P17 (1 mg/kg in 20 L). Vehicle control was PBS/DMSO 1:1.
Results and Discussion

3-PUFA Intervention Directly Attenuates Retinal NV
In the OIR mouse model, vascular loss develops during hyperoxic incubation from P7 to P12. After return to room air, the avascular areas of the retina become hypoxic and respond with upregulation of angiogenic growth factors like vascular endothelial growth factor (VEGF) (Figure 1a ). VEGF upregulation is followed by retinal neovessel formation seen morphologically from P15 onwards and displaying maximal severity at P17 (Figure 1b ). Because dietary 3-PUFAs are transferred from nursing mothers to the pups with some delay, 3-PUFA treatment was started at P14 to specifically target the active phase of NV formation from P15 onwards (Figure 1c ). At P17, 3-PUFA-fed mice show Figure 1 . 3-PUFA intervention reduces neovascularization. a, Wholeretinal VEGF expression in normoxic retinas and retinas with OIR normalized to Cyclophilin A. b, Quantification of retinal NV from mice with OIR at P15 and P17 and representative retinal flat mounts with NV in white (nՆ8 per group). c, Schematic of the mouse OIR model and 3-PUFA intervention. d, P17 Quantification of retinal NV and representative lectin-stained flat mounts from mice given either 3-or 6-PUFAs from P14 to P17. e, Quantification and representative flat mounts of retinal VO from the same mice at P17. Scale bars, 500 m. nՆ23 per group. *****PՅ10
Ϫ5
. White areas signify NV in d and VO in e. (Figure 1d ). Vasoobliteration (VO) at P17 is not affected (3 versus 6: 22.5Ϯ1.2 versus 21.5Ϯ1.3% VO; Pϭ0.6) (Figure 1e ). Enlarged retinal quadrants are shown in Online Figure I (a and  b) . The 6-diet with arachidonic acid or other 6-PUFAs did not significantly exacerbate retinal NV compared to standard rodent chow, indicating that the observed differences in NV formation are mainly attributable to a beneficial effect of 3-PUFAs (Online Figure I, c and d ).
Non-standard Abbreviations and Acronyms
These results demonstrate, for the first time, that 3-PUFAs can attenuate retinal NV formation directly, even when retinal hypoxia is already established and pathological neovascularization is in its active stage.
PPAR␥ Activation Is Required for 3-PUFA-Mediated Attenuation of NV
The rapidity by which 3-PUFA intervention attenuates NV suggests a receptor-based mechanism. We therefore investigated the involvement of the endogenous 3-PUFA receptor PPAR␥. 8 Pharmacological inhibition of PPAR␥ from P14 to P17 with the specific inhibitor GW9662 6,7 significantly reduces the inhibitory effects of 3-PUFAs on retinal NV (4.7Ϯ0.4 versus 7.2Ϯ0.4% NV; Pϭ0.0008) without altering retinal NV in 6 groups (7.4Ϯ0.5 versus 6.9Ϯ0.6% NV; Pϭ0.5) (Figure 2a and 2c ). VO at P17 was not altered in either group (21.8Ϯ1.5% versus 22.1Ϯ1.5% VO; Pϭ0.9 and 20.5Ϯ2% versus 20.8Ϯ1.5% VO; Pϭ0.9) (Figure 2b ). Original retinal images and enlarged quadrants are shown in Online Figure II . Notably, pharmacological inhibition of PPAR␥ also reduces the expression of PPAR␥ in circulating leukocytes from 3-fed mice to levels seen in the 6 control group (Online Figure III) .
These results identify PPAR␥ as a major pathway through which 3-PUFAs exert their beneficial effects on retinal neovascularization. The swiftness of the 3-PUFA effects and the near-complete abrogation with PPAR␥ inhibition indicate a central role for this transcriptional regulator in conveying the 3-PUFA effects. Importantly, pharmacological PPAR␥ activation with thiazolidinediones, used to control hyperglycemia in type II diabetes, similarly attenuates proliferative retinopathy both in animal models and in diabetic patients, 9,10 raising the possibility that 3-PUFAs might have clinical effects similar to pharmacological PPAR␥ activators. 
3-PUFA Intervention Reduces Retinal Inflammatory Activity via PPAR␥
Given that retinal VEGF levels were not altered by 3-PUFA intervention (Figure 3a and 3b) and given the known involvement of PPAR␥ in inflammatory modulation, 11 we hypothesized that 3-PUFAs might limit NV by modulating retinal inflammatory pathways. Tumor necrosis factor (TNF)␣ is a major inflammatory mediator whose expression is upregulated during the proliferative stage of OIR. 12 In P17 OIR retinas, TNF␣ localizes to retinal neovessels (arrows in Figure 3c ), as well as to macrophages associated with these neovessels (arrowheads in Figure 3c ). 3-PUFA treatment reduces TNF␣ protein both in retina and serum in a PPAR␥-dependent fashion (Figure 3d and 3e) . Similarly, murine macrophages incubated with 3-PUFAs (docosahexaenoic acid) in vitro express significantly less TNF␣ than those incubated with 6-PUFAs (arachidonic acid); a difference that is also dependent on PPAR␥ (Figure 3f ). Analogous to the retina, macrophage expression of VEGF is not modulated by 3 or 6 treatment in vitro (Figure 3g ). These results indicate that 3-PUFAs attenuate NV formation without altering the hypoxia-driven VEGF axis but by modulating the inflammatory state of the retina via PPAR␥. These findings are in line with data obtained with pharmacological PPAR␥ activators that reduce retinal TNF␣ and NV formation in the OIR model without changing VEGF overexpression 9, 13 and reduce TNF␣ levels in diabetic patients. 14 
3-PUFA Intervention Reduces Endothelial Cell Activation via PPAR␥
Besides modulating inflammatory mediators, 3-PUFAs can directly attenuate activation of endothelial cells (ECs). 15 EC activation is in part characterized by upregulation of adhesion molecules 16 and angiopoietin (Ang)-2 17 and renders ECs more responsive to angiogenic stimulation. Ang-2 in particular has been found to be expressed only weakly in resting endothelium but robustly following endothelial activation. 18 At P17, both Ang-2 and the adhesion molecule intercellular adhesion molecule (ICAM)-1 are expressed in activated ECs from retinal neovessels but not in quiescent vessels nearby (Figure 4a and 4b) . When neovessels are isolated using laser-capture microdissection (Figure 4c ), NV from 3 animals show a PPAR␥-dependent reduction of ICAM-1, VCAM-1 (vascular cell adhesion molecule-1), E-Selectin (endothelial selectin), and Ang-2 compared to 6 mice (Figure 4d through 4g ). In line with the mRNA data, 3-PUFAs reduce retinal Ang-2 protein, mediated in part via PPAR␥ (Figure 4h ). Ang-1 and ICAM-2 are not significantly regulated between 3-and 6 groups (Online Figure IV, a  and b) . Importantly, other nonendothelial cells closely associated with neovessels may also contribute to the inflammatory profile presented. Particularly neovessel-associated macrophages (Figure 3c ) may influence the local inflammatory milieu. This is illustrated by higher levels of local TNF␣ expression in laser-captured neovessels from 6 mice compared to 3 mice (Online Figure IV, c) .
In summary, this study demonstrates that 3-PUFA intervention during the proliferative phase of retinopathy decreases the neovascular activity of the retina via PPAR␥-dependent reduction of inflammatory mediators and attenuation of EC activation. The PPAR␥-dependent effect of 3-PUFAs on NV formation is large and comparable to anti-VEGF treatment in the OIR model. 4 This is the first study to identify a direct inhibitory effect of 3-PUFAs on retinal neovascularization and the first to identify PPAR␥ as one of the major pathways mediating this effect. Because retinal VEGF levels are unaffected, 3-PUFA-dependent activation of PPAR␥ might be considered as an additive treatment to the current anti-VEGF approaches for pathological retinal angiogenesis. 
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Novelty and Significance
What Is Known
• Omega3 long-chain polyunsaturated fatty acids (3-PUFAs) are angiogenic modulators that can attenuate the severity of retinal neovascularization (NV).
• Whether 3-PUFAs exert a direct effect on retinal neovessel formation and what mechanisms might be involved, remained unknown.
What New Information Does This Article Contribute
• By specifically targeting the neovascular phase of proliferative retinopathy (phase II), this study identifies, for the first time, a direct beneficial effect of 3-PUFAs on retinal NV formation during the active proliferative phase.
• This study identifies peroxisome proliferator-activated receptor (PPAR)␥ as a major pathway through which 3-PUFAs exert their beneficial effects on NV formation. We have shown previously that 3-PUFAs given before the onset of retinopathy can attenuate disease severity. In many patients, however, retinopathy is diagnosed when the disease has already progressed to active neovascularization. This study investigated whether the known endogenous 3-PUFA receptor PPAR␥ is involved in mediating a potential direct effect of 3-PUFAs on retinal neovessel formation. Our study demonstrates that 3-PUFAs given selectively during the neovascular phase of retinopathy directly reduce retinal neovessel formation without altering vasoobliteration or regrowth of normal vessels. Mechanistically, we identify PPAR␥ as a major mediator for the 3-PUFA effect that acts independent of VEGF through modulation of inflammatory mediators and reduced angiogenic activation of retinal endothelial cells. 3-PUFAs might thus be considered as an additive treatment to anti-VEGF therapies. . n is number of eyes quantified.
ω3-PUFA intervention.
Dietary PUFAs were produced by DSM Nutritional Products under the trade name ROPUFA.
The arachidonic acid and DHA supplements, under the trade names ARASCO and DHASCO respectively, were obtained from Martek Biosciences Corporation. The feed was produced at
Research Diets Incorporated. The composition of this diet has been described in detail earlier and lipids in the diet had been found to be stable over time with respect to oxygen exposure over the course of the experiments and with cold storage of feed for a year 3 . The reasoning behind comparing the ω3-diet to an ω6-diet instead of "normal chow" is that normal rodent chow contains an undefined combination of fatty acids that can vary from batch to batch. Normal chow might therefore deliver varying amounts of both ω3-and ω6-FAs to the pups in the control group. Using defined feed +/-ω3-PUFAs is not feasible either. The group receiving defined feed without ω3-PUFAs would obtain less total fatty acids and less total calories compared to the group receiving defined feed + ω3-PUFAs.Thus, the control group must consist of defined feed with some other (non ω3-) PUFAs to balance out total fat content. Using strucutrally similar ω6-PUFAs in the control group provides a control feed that is isocaloric and equal to the ω3-feed in total fatty acid content. Importantly, ω6-feed does not induce any negative effect on NV formation compared to normal chow (Online Fig. Ib) .
Immunohistochemistry.
For immunohistochemistry, eyes were enucleated and fixed in 4% paraformaldehyde at room temperature for 1h. The retina was isolated, permeabilized overnight at 4 ºC with 0.5% Triton X- TNFα and VEGF protein ELISA. Retinal and/or serum samples were quantified for TNFα or VEGF protein using a commercially available ELISA system (R&D Systems). For retinal samples, three retinas from different mice were pooled, homogenized and sonicated in 1%
Nonidet P40 in PBS (Roche Diagnostics) containing an array of phosphatase and protease inhibitors (Sigma). Samples were normalized using a BCA assay (Pierce). For serum samples,
